Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 250 | 0.82 |
| pathways Reactome | 4 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 3458
Sealed predictions
- SH2B1 in dopamine neurons, braak-0.26 (p 0.493) → -0.63 (p 0.068)receipt 3464
Swarm cases
receipt 3464: SH2B1 in dopamine neurons, braak
- power
- full sample -0.40 (p 0.101, n 18), 95% CI -0.73 to +0.08. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.46 (p 0.052, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.48 (p 0.043, n 18). not the mix.
- skeptic
- leave-one-out range -0.57 to -0.33, sign flips 0; without severely affected donors -0.40 (p 0.101, n 18). fragile.
- cell type
- strongest in microglia: -0.63 (p 0.0053, n 18) vs -0.40 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SH2B1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SH2B1 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.80 p 0.0045 (needs p < 5.3e-4)
Receipts
loading the receipts